New York Genome Center

Name

New York Genome Center

Legal name

New York Genome Center, Inc.

Website

https://nygenome.org

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Genomics Research Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro industry

PRIMARYHLAGANAA

Genomics & Next-Generation Sequencing (NGS) Services

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

SECONDARYHLAGADAF

Molecular & Genetic Testing (PCR/NGS/qPCR)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Laboratory Testing & Analytical Services

SECONDARYHLAFAMAE

Molecular Diagnostics & Genomics Laboratories

Healthcare & Life Sciences/Healthcare Providers & Systems/Clinical Laboratories

SECONDARYHLAGANAE

Transcriptomics & Gene Expression Profiling Services

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

SECONDARYHLAGAIAF

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Laboratory Equipment, Instruments & Consumables

Keywords

• Genomic sequencing services
• Clinical genetic testing
• Bioinformatics analysis
• Collaborative genomic research
• Precision medicine tools

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Genomics and Bioinformatics Services: NYGC provides sequencing and bioinformatics services to the academic and scientific communities. Pricing is quote-based as outlined in service agreements. Results are provided for research purposes only.
2. Research Grants and Funding: As a nonprofit academic research institution (501(c)(3)), NYGC receives significant funding from government agencies (NIH grants totaling $143M under management as of 12/2025), private foundations (The Warren Alpert Foundation, The Mark Foundation, etc.), and individual donors.
3. Clinical Genetic Testing: State-of-the-art clinical diagnostic laboratory utilizing next-generation sequencing technology for cutting-edge genetic tests in genetics and oncology. CLIA-certified and licensed in all 50 U.S. states and D.C.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

NYGC provides genomic sequencing, bioinformatics analysis, and CLIA-certified clinical genetic testing services to academic, medical, and industry clients. The organization operates advanced technology platforms for next-generation sequencing, single-cell profiling, and CRISPR-based research while running collaborative research programs in cancer genomics (Polyethnic-1000), neurodegenerative disease (ALS Consortium), and neuropsychiatric disease. NYGC develops and distributes proprietary computational tools (Lancet2, Cas13design, PrecisionChain) and novel methodologies (D&D-seq, scG2P, PATH) for the scientific community.

Product overview

NYGC operates as a multi-institutional hub for collaborative genomic research, offering a portfolio of genomics services and internally developed tools. The core offerings include a CLIA-accredited Clinical Genetics Laboratory for diagnostic testing, Research Sequencing services, and Technology Development platforms including Computational Biology. Key products include Cas13design (RNA-targeting CRISPR guide RNA design tool), PrecisionChain (blockchain-based data sharing platform), and Lancet2 (variant detection software). NYGC also conducts collaborative research through initiatives like Polyethnic-1000 (cancer genomics in diverse populations) and the ALS Consortium. The institution develops specialized methodologies such as D&D-seq (single-cell DNA-protein mapping), PATH (tumor plasticity quantification), and scG2P (single-cell mutation mapping) through its faculty labs.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Genetics Laboratory CLIA-accredited clinical diagnostic laboratory providing cutting-edge genetic testing services in genetics and oncology using next-generation sequencing technology. Licensed in all 50 U.S. states and D.C. and participates in CAP proficiency testing. Serves healthcare providers and clinical laboratories requiring state-of-the-art clinical genetic testing and precision medicine capabilities.
• Research Sequencing Advanced sequencing services providing whole genome and targeted sequencing for academic and research institutions. Supports collaborative research programs across multiple disease areas with 195K+ Whole Genome Equivalents Sequenced to date. Priced via quotation with results provided for research purposes only.
• Technology Development Multidisciplinary team developing innovative genomic tools and technologies including novel sequencing methods, CRISPR applications, and computational pipelines. Drives NYGC's proprietary method development including D&D-seq, scG2P, and other breakthrough approaches.
• Computational Biology Lab Technology platform providing computational biology expertise and bioinformatics capabilities to support genomic research, including data analysis, algorithm development, and biological interpretation. Led by Senior Vice President of Informatics Dr. Michael Zody.
• Polyethnic-1000 Collaborative research initiative advancing cancer genomics in diverse populations, studying cancers in minority patients including bladder, pancreatic, breast, prostate, colon, endometrial, and lung cancers. Funded by The Mark Foundation for Cancer Research, Illumina Inc., and other philanthropic supporters.
• ALS Consortium Multi-institutional collaboration focused on ALS research and care, working with Target ALS, ALS United Greater New York, Eleanor and Lou Gehrig ALS Center at Columbia University, and academic medical centers. Led by Dr. Hemali Phatnani, Director of the Center for Genomics of Neurodegenerative Disease.
• Cas13design Web-based tool and open-source platform for designing optimized Cas13 guide RNAs to target RNA transcripts. Integrates machine learning-based predictive models for guide efficiency across human transcriptome, model organisms, and viral RNA genomes. Available as web tool and open-source toolbox for the research community.
• PrecisionChain Blockchain-based data sharing and analysis platform for precision medicine that securely stores, harmonizes, shares, integrates, and analyzes both genetic and clinical data. Uses OMOP Common Data Model and Variant Call Format (VCF) for data harmonization. Provides interactive Jupyter Notebooks for analysis.
• Lancet2 Open-source computational method that significantly improves detection of somatic variants across the genome. Uses local assembly and joint analysis of tumor and matched normal sequencing data with explainable machine learning for variant scoring. Achieves ~10x speed improvement and 50% memory reduction versus original Lancet.
• D&D-seq (Docking and Deaminase Sequencing) Single-cell method for mapping DNA-protein interactions. Uses antibodies to bring a DNA-editing enzyme close to target proteins, allowing researchers to record where proteins interact with DNA. First method easily incorporated into high-throughput single-cell multi-omics workflows enabling combined genome, transcriptome, and proteome analyses.
• scG2P (single-cell Genotype-to-Phenotype) Single-cell profiling technique that maps pre-malignant gene mutations in solid tissues for the first time. Analyzes clonal driver mutations in esophageal tissue samples and other solid tissues, enabling cancer researchers to study tumor evolution at single-cell resolution.
• PATH (Phylogenetic Analysis of Trait Heritability) Analytical tool to quantify tumor cell plasticity, measuring how tumor cells 'shape-shift' to become more aggressive and treatment-resistant. Identifies key transitional cell states in cancer progression using lineage information (DNA markers) and cell state data from gene activity, surface receptors, or spatial locations.

Quantifiable outcome

• 195K+ Whole Genome Equivalents Sequenced
• +3 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability12 records

Feature9 records

Partnerships

18 partnerships are on record, tiered core and minor.

• Mission Bio Inc.coreStrategic or Co-development Partner · 16 January 2026Collaboration with Weill Cornell Medicine and Mission Bio Inc. to develop the scG2P single-cell profiling technique that maps pre-malignant gene mutations in solid tissues. Published in Cancer Discovery journal. Mission Bio provides single-cell technology expertise for the research initiative.
• Weill Cornell MedicinecoreStrategic or Co-development PartnerPrimary collaborative research partner with joint faculty appointments. Multiple joint research programs including cancer research, Landau Lab studies on cancer detection from blood tests, bladder cancer genomics with Dr. Bishoy Faltas, and computational biology collaborations.
• Target ALScoreStrategic or Co-development PartnerNYGC ALS Consortium collaborates with Target ALS on ALS research initiatives. Dr. Hemali Phatnani serves as Director of NYGC's Center for Genomics of Neurodegenerative Disease and works with Target ALS to develop treatments for ALS.
• Columbia UniversitycoreStrategic or Co-development PartnerFounding institutional member with multiple joint faculty appointments. Dr. Bing Ren holds joint appointment as professor in Departments of Genetics and Development, Biochemistry and Molecular Biophysics, and Systems Biology. Dr. Gamze Gürsoy holds appointment as Herbert Irving Assistant Professor of Biomedical Informatics at Columbia.
• Cold Spring Harbor LaboratorycoreStrategic or Co-development PartnerFounding institutional member collaborating on Polyethnic-1000 cancer genomics research initiative. Joint research on pancreatic cancer, colorectal cancer, and endometrial cancer disparities in minority populations.
• New York UniversitycoreStrategic or Co-development PartnerFounding institutional member with joint faculty appointments. Dr. Neville Sanjana holds appointment as Associate Professor of Biology at NYU. Dr. Rahul Satija is Associate Professor at NYU's Center for Genomics and Systems Biology. Joint CRISPR technology development through Sanjana Lab.
• ALS United Greater New YorkminorStrategic or Co-development PartnerCollaboration on NYGC ALS Consortium contributing to New York State Governor's proposed $25 million ALS research and care program.
• Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerFounding institutional member participating in Polyethnic-1000 cancer genomics initiative, including multiple myeloma research in collaboration with NYU.
• Northwell HealthminorStrategic or Co-development PartnerFounding institutional member contributing to Polyethnic-1000 collaborative cancer research projects including pancreatic cancer and endometrial cancer disparity studies.
• The Rockefeller UniversitycoreStrategic or Co-development PartnerFounding institutional member supporting collaborative genomic research across NYGC's research programs.
• Icahn School of Medicine at Mount SinaiminorStrategic or Co-development PartnerFounding institutional member collaborating on Polyethnic-1000 research, including breast and prostate cancer disparity studies.
• Stony Brook UniversitycoreStrategic or Co-development PartnerFounding institutional member contributing to NYGC's collaborative research ecosystem.
• NewYork-Presbyterian HospitalcoreStrategic or Co-development PartnerFounding institutional member supporting cancer research and clinical care collaborations with NYGC.
• Eleanor and Lou Gehrig ALS Center at Columbia UniversityminorStrategic or Co-development PartnerPartner in NYGC ALS Consortium contributing to New York State Governor's proposed $25 million ALS research and care program.
• University of Rochester Medical CenterminorStrategic or Co-development PartnerPartner in NYGC ALS Consortium contributing to New York State Governor's proposed $25 million ALS research and care program.
• BC Cancer Research InstituteminorStrategic or Co-development PartnerDr. Samuel Aparicio serves as Senior Scientific Director of Cancer Genomics at NYGC while maintaining position at BC Cancer. Joint research on breast tissue aging and cancer risk published in Nature Aging.
• University of CambridgeminorStrategic or Co-development PartnerInternational research collaboration with Dr. Samuel Aparicio on breast tissue aging study published in Nature Aging.
• Brown UniversityminorStrategic or Co-development PartnerCollaboration on single-cell data privacy risk quantification study with researchers from Columbia University and Brown University.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Market position

Strengths5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/nygenome
• LinkedInlinkedin.com/company/new-york-genome-center
• Facebookfacebook.com/nygenome

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about New York Genome Center